Nuwellis, Inc. entered into a securities purchase agreement on July 31, 2026, to sell 1,310,890 shares of common stock at $2.59 per share in a registered direct offering. Concurrently, the company issued warrants to purchase an equal number of shares with an exercise price of $2.59 and a five-year term. Ladenburg Thalmann & Co. Inc. acted as placement agent for approximately $3.4 million in gross proceeds, closing on August 3, 2026. The filing also notes that Nuwellis received $3.1 million from the exercise of previously issued warrants from a June 2026 public offering. Nuwellis operates in the medical technology industry, providing solutions for patients with cardiorenal conditions.
